ENXTAM:PHARMBiotechs
Assessing Pharming Group (ENXTAM:PHARM) Valuation After Mixed Momentum And Joenja Growth Expectations
Why Pharming Group (ENXTAM:PHARM) is on investors’ radar
Pharming Group (ENXTAM:PHARM) has caught investor attention after a period of mixed share performance, including a negative return over the past month but a positive total return over the past year.
At a last close of €1.35 and with reported annual revenue of €362.27 million and net income of €0.38 million, the company presents a specific profile in rare disease protein replacement and precision medicines.
See our latest analysis for...